The Risky Bet Behind The First "Artificial Pancreas" For Diabetes Patients
Twelve years ago, a dotcom millionaire stood at a patient advocacy group’s board meeting and made an offer.
I’ll give you $1 million, he said. But only if you commit to getting an artificial pancreas on the market.
That challenge set JDRF, formerly known as the Juvenile Diabetes Research Foundation, on a costly, and risky, campaign to enlist academic researchers, global companies, members of Congress, and even federal regulators to embrace the concept of a device that could take over much of the process of regulating blood sugar in patients with diabetes.
I’ll give you $1 million, he said. But only if you commit to getting an artificial pancreas on the market.
That challenge set JDRF, formerly known as the Juvenile Diabetes Research Foundation, on a costly, and risky, campaign to enlist academic researchers, global companies, members of Congress, and even federal regulators to embrace the concept of a device that could take over much of the process of regulating blood sugar in patients with diabetes.